Shares of biotechnology specialist Argenx (NASDAQ: ARGX ) — which focuses on addressing severe autoimmune diseases – suffered a hefty decline on Wednesday following a clinical disappointment. Its P...

Argenx SE (NASDAQ: ARGX) says a late-stage trial of its candidate drug for an autoimmune condition failed to meet the primary or secondary endpoints. Its shares are down 25% at writing.

Argenx stock ARGX, -33.70% ARGX, -0.64% lost a third of its value as the Amsterdam biotech said a late-stage trial did not meet primary or secondary endpoints. The Phase 3 study was of using efgart...

Stock markets looked ready to ease lower Tuesday morning after big gains earlier in the month. Zscaler stock fell back even with strong results in its fiscal first quarter.

In the world of investing, it's often the hidden gems that yield the most extraordinary returns. While Wall Street keeps a watchful eye on the giants, lesser-known stocks are quietly charting a cou...

argenx SE (NASDAQ:ARGX ) Q3 2023 Earnings Conference Call October 31, 2023 8:30 AM ET Company Participants Beth DelGiacco - VP and Global Head, Corporate Communications and IR Tim Van Hauwermeiren ...

October 24, 2023 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, tod...

argenx exhibits robust financials with a Q2 YoY net sales surge to $269.3M and liquidity of $2.0B but faces increasing operating costs and R&D expenditures. Efgartigimod, ARGX's primary asset, show...

The stock gapped up nearly 28% on July 17, after announcing better-than-expected results from a clinical trial of its treatment for patients suffering from a progressive condition that affects musc...